host response in infectious disease and sepsis (https://t.co/PGUR7jw62Z). co-founder & CEO, @Inflammatix_inc (https://t.co/2qSdXykwDw). reformed surgeon.
Mar 19, 2019 • 10 tweets • 5 min read
Thrilling to see so much focus on #sepsis endotyping and reducing heterogeneity at #ISICEM19@ISICEM! For the non-expert, perhaps a brief review is helpful: /1
Lots of prognostic tools for #sepsis exist, and many are well-validated. Although endotypes often show outcomes differences at baseline, they are NOT for outcomes prediction! Purpose-built tools and biomarkers are better for this. /2